It was also on the July agenda. Meeting minutes should be posted in a day or two. Assuming this is Amarantus which I do, it's a good sign they are back on the agenda for the following meeting vs. being sent packing.

RP seemed rather straight forward. A number of companies have submitted for RP orphan over the years. I haven't see the same activity for RAO. Actually none, but haven't spent a very long time looking. Two orphans on MANF would be incredible. One is great. Two is even better. I already posted the deal AGTC got with two orphans in ophthalmology with one reaching clinical (pipeline -> http://www.agtc.com/products)

Here's the July meeting:

Committee for Orphan Medicinal Products (COMP)
Draft agenda for the meeting on 14-16 July 2015


2.2.13. - EMA/OD/079/15
Treatment of retinal artery occlusion
Action: For adoption
Documents tabled:
Draft Summary report

http://www.ema.europa.eu/docs/en_GB/document_...189364.pdf


Here's the link to watch:

http://www.ema.europa.eu/ema/index.jsp?curl=p...0580028e78